主页文献库搜索
Comorbidity and survival of prostate cancer D3 patients.

Cogswell(J),Badin(S),Oliphant(T L),Hoover(... J Clin Oncol 0000-00-00

...alkaline phosphatase (AlkPhos), hemoglobin (hgb), and prostate specific antigen (PSA). The number of radiation and chemo...

Risk stratified analysis improves prediction of treatment (Rx) benefit over s...

Sanoff(H K),Campbell(M E),Pitot(H C),Goldb... J Clin Oncol 0000-00-00

...alkaline phosphatase (ALK), and ECOG performance score (PS). Low risk: PS 0/1 and 1 site. Intermediate risk: PS 0/1, >1 ...

NCCTG phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients wit...

Kim(G P),Oberg(A),Kabat(B),Sing(A),Hedrick... J Clin Oncol 0000-00-00

...alk phos (3), dehydration (3), thrombosis (2), leukopenia (2), neutropenia (4), abdominal pain (2), hypokalemia (4), and...

Prostate cancer immunohistochemical (IHC) stains and survival in stage D3 pat...

Gounder(S K),Chang(V T),Hoover(D),Gonzalez... J Clin Oncol 0000-00-00

...Alkaline Phosphatase (Alk Phos), Prostate Specific Antigen (PSA), Lactate Dehydrogenase (LDH) levels at the time of D3 s...

Correlation of statin use and duration with increased survival in hormone ref...

Rich(N T),Smith(B J),Vaena(D A) J Clin Oncol 0000-00-00

...Alk Phos, Gleason, PSA). An LDH value of 90 U/L (low-normal at ICVA) was used for all patients, since LDH values were no...

Phase I trial of subcutaneous (SQ) alemtuzumab (A) and CHOP in T-cell lymphom...

Porcu(P),Baiocchi(R A),Lee(J),Lin(T S),Blu... J Clin Oncol 0000-00-00

...ALK-1-positive anaplastic large cell lymphoma.,maximal tolerated dose (MTD). All pts receive single agent SQ A loading (...

A phase II study of HCVIDDOXIL alternated with methotrexate-cytarabine in pat...

Pro(B),Fayad(L),Romaguera(J),Hagemeister(F... J Clin Oncol 0000-00-00

...ALK +, T-anaplastic large cell lymphoma (ALCL), HIV-1 positive serology, and evidence of CNS involvement were excluded. ...

CHOP/CHOEP-14 followed by consolidation with alemtuzumab in untreated aggress...

Trumper(L H),Hohloch(K),Kloess(M),Dührsen(... J Clin Oncol 0000-00-00

...ALK negative); age 18-70 y; all IPIs; ECOG PS 0-3. The primary endpoint is feasibility, measured by occurrence SAE and p...

BEAM-alemtuzumab followed by allogeneic SCT for the treatment of relapsed or ...

Repp(R),Günther(A),Schade(H),Humpe(A),Gahn... J Clin Oncol 0000-00-00

...ALK negative ALCL, 1 extranodal NK/nasal type and 1 enteropathy-type T-NHL. All patients had at least 2 different treatm...

Bony metastatic disease responses to sorafenib (BAY 43-9006) independent of P...

Dahut(W L),Scripture(C D),Posadas(E M),Wu(... J Clin Oncol 0000-00-00

...Alk Phos 108 u/l (48-259), Hb 12.7 g/dl (10.2-15.1). 60% of patients had received one prior chemotherapy regimen. Of the...

上一页 635 636 637 638 639 640 641 642 643 下一页 639 / 共 646

联系地址

山东省济南市章丘区文博路2号

齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号

大学科技园北区F座4单元2楼

电话: 0531-88819269

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。


商务邮箱

E-mail: product@genelibs.com